RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Archives of Internal Medicine Pharmacology Channel

subscribe to Pharmacology newsletter
Latest Research : Pharmacology

   EMAIL   |   PRINT
Prescribers fail to follow black box warnings

Feb 15, 2006 - 3:03:00 PM , Reviewed by: Priya Saxena
"The Food and Drug Administration should make these warnings more specific, so that they are readily understandable by providers, and so that such providers can easily take action to avoid violating the warnings."

 
[RxPG] Less than 1 percent of outpatients who received medication in 2002 were prescribed a medication that violated a prescription drug's black box warning, according to a study in the February 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

"Adverse drug events (ADEs) are believed to be among the leading causes of mortality in the United States, with an estimated 100,000 deaths per year," according to background information in the article. However, there is little U.S. data on the occurrence of potentially dangerous drug-drug, drug-laboratory, and drug-disease interactions in outpatients. Black box warnings are separate, highlighted messages on drug labels that were developed by the Food and Drug Administration to help physicians avoid serious ADEs.

Karen E. Lasser, M.D., M.P.H., of Cambridge Health Alliance and Harvard Medical School, Cambridge, Mass., and colleagues, examined data from 51 outpatient practices to see how often physicians prescribed drugs in violation of black box warnings. The researchers analyzed electronic health records of 324,548 outpatients who received at least one prescription between January 1 and December 31, 2002.

The researchers found that 0.7 percent (2,354) of those outpatients received a prescription in violation of a black box warning. Of these patients who received a prescription with a black box warning, most (90.6 percent) were at risk for a drug-disease interaction, followed by a drug-laboratory interaction (26.6 percent; patient did not receive adequate monitoring) and a drug-drug interaction (3.3 percent). Patients who were white, female and 75 years of age or older and who took more medications were significantly more likely to be prescribed medications in violation of black box warnings. The researchers then analyzed a sample of 575 of the 2,354 patient records with prescriptions in violation of black box warnings and found that less than 1 percent of those patients had a documented adverse drug reaction as a result.

The researchers commented that similar studies have shown that prescribers fail to follow black box warnings much more frequently than observed in this study.

"We believe these data have implications for the Food and Drug Administration," the researchers write. "The Food and Drug Administration should make these warnings more specific, so that they are readily understandable by providers, and so that such providers can easily take action to avoid violating the warnings."



Publication: The study appears in the February 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals
On the web: http://jama.ama-assn.org/ 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacology News
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Research shows promise for microwave ablation to relieve painful bone and soft-tissue tumors
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
Research examines effects of opioids on patients with sickle cell disease
Full range of treatment settings and their effects on radiofrequency heat lesion size
High-dose opioids disturb hormones long-term, but mental and physiologic function improves
Web-based tools found to enhance recruitment and prescreening for clinical pain trials
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study: Pain improves during first year but mental-health problems linger

Subscribe to Pharmacology Newsletter

Enter your email address:


 Additional information about the news article
(Arch Intern Med. 2006; 166: 338 - 344)

Editor's Note: This study was supported by grants from the Harvard Risk Management Foundation, and by Partners HealthCare Information Systems, Boston. A full financial disclosure is listed in the article.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)